[Form 4] CalciMedica, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Eric W. Roberts, identified as a Director, 10% owner and Chief Business Officer of CalciMedica, Inc. (CALC), reported a purchase of 2,500 shares of the issuer's common stock on 09/18/2025 at a price of $3.07 per share. The Form 4 lists multiple existing direct and indirect holdings across custodial and SPV accounts. The filing was signed by an attorney-in-fact on 09/22/2025.

Insights

Financial Analyst

TL;DR Insider reported a small open-market purchase; filing is routine and provides updated ownership detail.

The reported acquisition of 2,500 shares at $3.07 is explicitly disclosed and updates Eric Roberts' beneficial ownership across several custodial and SPV accounts. The transaction appears to be a straightforward purchase rather than an issuance or derivative exercise. Based solely on the document, there is no additional financial data or company guidance to indicate material impact on CalciMedica's valuation.

Corporate Governance Expert

TL;DR Form 4 is a standard disclosure showing insider activity and updated beneficial ownership; no governance change disclosed.

The filing confirms Roberts' roles (Director, 10% owner, Chief Business Officer) and provides custodial details for indirect holdings. The presence of an attorney-in-fact signature is noted. There is no disclosure of leadership change, related-party transaction, or any new agreement affecting governance in this form.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roberts Eric W

(Last) (First) (Middle)

C/O CALCIMEDICA, INC.

505 COAST BLVD. S. #307

(Street)

LA JOLLA CA 92037

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF BUSINESS OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/18/2025		P		2,500	A	$3.07	84,150	I	By FMTC Custodian - Roth IRA FBO Eric W. Roberts
Common Stock								179,706	D
Common Stock								49,894	I	By Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA
Common Stock								10,661	I	By IRA Financial Trust Company CFBO Eric W. Roberts
Common Stock								356,989	I	By Valence Investments SPV IV, LLC
Common Stock								66,228	I	By Valence Investments SPV V, LLC
Common Stock								316,109	I	By Valence Investments SPV VI, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ John Dunn, Esq., Attorney-in-Fact	09/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Eric W. Roberts report on the Form 4 for CALC?

The Form 4 discloses a purchase of 2,500 shares of CalciMedica common stock on 09/18/2025 at $3.07 per share.

What roles does the reporting person hold at CalciMedica (CALC)?

The filing lists Eric W. Roberts as a Director, a 10% owner, and the company's Chief Business Officer.

When was the Form 4 signed and by whom?

The Form 4 was signed by John Dunn, Esq., Attorney-in-Fact on 09/22/2025 according to the document.

Does the Form 4 show total beneficial ownership after the transaction?

The form lists multiple direct and indirect holdings by account or entity; specific aggregated total is not explicitly summed in the document.

Are there any derivative transactions reported on this Form 4?

No derivative securities (options, warrants, convertible instruments) are reported in Table II of this filing.